05:06 PM EDT, 05/06/2025 (MT Newswires) -- Sarepta Therapeutics ( SRPT ) reported a Q1 non-GAAP loss Tuesday of $3.42 per diluted share, compared with earnings of $0.72 per share a year earlier.

Analysts polled by FactSet expected earnings of $2.52.

Revenue in the three months ended March 31 rose to $744.9 million from $413.5 million a year earlier.

Analysts surveyed by FactSet expected $687.5 million.

The company cut 2025 net product revenue guidance to the range of $2.3 billion to $2.6 billion from $2.9 billion to $3.1 billion.

The company's shares tumbled 21% in after-hours trading.